Ticlopidine Hydrochloride Tablets

Ticlopidine is a platelet aggregation inhibitor. Platelet activation is affected by many factors, among which adenylate diphosphate (ADP) plays a key role. When adenylate diphosphate binds to its specific receptor, it can activate the fibrin membrane receptor (glycoprotein II_III complex) on the surface of the platelet membrane, and bind to fibrinogen to cause platelet aggregation (phase I aggregation). Ticlopidine has a strong inhibitory effect on ADP-induced platelet aggregation (including phase I and phase II aggregation), and the effect is long-lasting. In addition, ticlopidine can reduce fibrinogen concentration and blood viscosity, and increase the filtration rate of whole blood and red blood cells.

Main ingredients: Ticlopidine hydrochloride.

Sugar-coated tablets are white or off-white after removing the sugar coating.

This product is suitable for preventing thromboembolic diseases associated with cerebrovascular, cardiovascular and peripheral arteriosclerosis, including first and recurrent stroke, transient ischemic attack and monocular visual loss, coronary heart disease and intermittent claudication, etc. It can also be used in extracorporeal circulation cardiac surgery to prevent platelet loss and chronic renal dialysis to increase the function of the dialyzer.

Oral: 1 tablet (0.25g) once a day, taken with meals to reduce mild gastrointestinal reactions.

Mild gastrointestinal reactions are occasionally seen. Rare reactions: nausea, diarrhea, rash, ecchymosis, gingival bleeding, leukopenia, cholestasis, mild elevation of aminotransferase, mucocutaneous bleeding tendency. The most common adverse reactions of this product are granulocytopenia or agranulocytopenia (2.4%), thrombocytopenia (0.4%), gastrointestinal disorder and rash. The above adverse reactions often occur within 3 months after medication. Occasionally, there are reports of granulocytopenia, thrombocytopenia and thrombotic thrombocytopenic purpura (Thromboticthrombocytopenic purpura, TTP) after several years of medication. Severe agranulocytopenia or TTP can even be fatal. Gastrointestinal reactions are mostly manifested as nausea, vomiting, and diarrhea, which are generally mild and do not require discontinuation of the drug. They can often recover after 1-2 weeks.

Patients with hemophilia or other bleeding disorders, patients with granulocytopenia or thrombocytopenia, ulcer disease and active bleeding should not use this drug. Patients with severe liver damage often increase the risk of bleeding due to coagulation factor synthesis disorders, so this product should not be used. People who are allergic to this product.

Precautions for children: The safety and effectiveness of this product in children are not yet clear. Precautions for pregnancy and lactation: This product can pass through the placental barrier and enter breast milk, so it should be avoided in pregnant and lactating women. Precautions for the elderly: The safety and effectiveness of this product in the elderly are not yet clear.

The combination of this product with any platelet aggregation inhibitor, thrombolytic agent, and drug that causes low coagulation plateau syndrome or thrombocytopenia can increase the risk of bleeding. If it is clinically necessary to use the drug together, close observation and laboratory monitoring should be performed. When this product is used in combination with theophylline, the blood concentration of theophylline will increase and there is a risk of overdose because it reduces the clearance rate of the latter. Therefore, the dosage of theophylline should be adjusted during and after the use of this product, and the blood concentration of theophylline should be monitored when necessary. When this product is used in combination with dimethoate, the blood concentration of the latter can be reduced (about 15%), but it generally does not affect the clinical efficacy of dimethoate. Occasionally, there are reports that this product reduces the blood concentration of cyclosporine, so the blood concentration of cyclosporine should be monitored regularly when the two are used in combination.

Keep away from light and store in a sealed container.

0.25 g

36 months